Method for preparing lactobionic acid-crosslinked hepatic cell targeted viral vector

Abstract

The invention provides a method for preparing a lactobionic acid-crosslinked hepatic cell targeted viral vector. The method comprises the following steps of: I, constructing a gene of a rotavirus structural protein VP2 or VP6 onto a protein expression plasmid pET series vector to obtain an expression plasmid pET-VP2 or pET-VP6; II, transforming the expression plasmid pET-VP2 or pET-VP6 into escherichia coli, and giving expression to an inclusion body protein IB; III, performing renaturation and refolding on the inclusion body protein IB to form a protein R-VP2 or R-VP6; IV, crosslinking the protein R-VP2 or R-VP6 and an anti-cancer drug to form a conjugate; V, performing self-assembling on the conjugate to form a virus-like particle carrying the anti-cancer drug; and VI, covalently crosslinking targeted ligand lactobionic acid onto the outer surface of the virus-like particle carrying the anti-cancer drug to obtain the lactobionic acid-crosslinked hepatic cell targeted viral vector. According to the lactobionic acid-crosslinked hepatic cell targeted viral vector prepared by the method provided by the invention, a hepatocellular carcinoma cell HepG2 can be specifically identified, so that the carried drug can be released in the hepatocellular carcinoma cell and generates cytotoxicity, and a new way is provided for targeted drug treatment of hepatocellular carcinoma.

Description

technical field [0001] The invention belongs to the technical field of viral proteins, and in particular relates to a preparation method of a lactosylated liver cell-targeting viral vector. Background technique [0002] Liver cancer is one of the most common tumors, and its incidence is increasing worldwide, seriously endangering human life and health. The current methods of treating liver cancer mainly include chemotherapy, surgery, intervention and other means, but the effect is not satisfactory. With the development of genetic science and technology, gene therapy for liver cancer has become possible. The key issue of gene therapy is the carrier of the gene. At present, the technology in this field is developing rapidly. The commonly used gene therapy carriers for liver cancer mainly include viral vectors, liposomes, plasmids, and cationic polymers. Among them, viral vectors have high efficiency, but poor specificity, and their application has not been ideal. [0003] L...

AI Technical Summary

Problems solved by technology

Among them, viral vectors have high efficiency, but poor specificity, and the application has not been ideal

Images